The influence of age on treatment responses in relapsing-remitting multiple sclerosis


  • Sustained exposure to disease-modifying therapies (DMT) can reduce the risk of disability worsening in relapsing-remitting multiple sclerosis (RRMS); however, effectiveness is lower in older individuals.

Why this matters

    The use of real-world data provides further evidence to support treatment decision-making in younger and older populations, of which are often underrepresented in clinical trials.

International Medical Press is a global provider of independent medical education. Its mission is to provide healthcare professionals with high-quality, trusted medical information with the aim of helping optimize patient care.

No responsibility is assumed by International Medical Press for any injury and/or damage to persons or property through negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein. Because of rapid advances in the medical sciences, International Medical Press recommends that independent verification of diagnoses and drug dosages should be made. The opinions expressed do not reflect those of International Medical Press or the sponsor. International Medical Press assumes no liability for any material contained herein.